InvestorsHub Logo
Followers 5
Posts 268
Boards Moderated 0
Alias Born 08/12/2022

Re: None

Monday, 08/15/2022 11:23:16 AM

Monday, August 15, 2022 11:23:16 AM

Post# of 1456
slapped the ask here a little. Let's go, Just closed an hourly over the 50 day moving average. Lots of catalysts as this deep oncology pipeline of 10 drugs moves forward with a Phase 3 commencing soon. One of only a few ROR1 assets in the clinic with outstanding data Merck bought one. & so

Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC.

https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc


Boehringer inks $1.5B NBE buyout, joining Merck in new ROR1 cancer race.

https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race

Oncternal Therapeutics Jumps on Bullish Oppenheimer Initiation
Oncternal was initiated with an outperform rating and a $14 price target. ... Oncternal Therapeutics (ONCT) -

HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated

At the European Hematology Association (EHA) meeting, Oncternal Therapeutics Inc (NASDAQ: ONCT) presented initial preclinical results of Oncternal's ROR1 CAR containing the antigen-binding region of zilovertamab.

ONCT Pipeline.
https://www.oncternal.com/pipeline

$ONCT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News